Abstract:Objective: The causes of hair loss are multifactorial; therefore, there are multiple potential targets for treatment, and a combination of different active ingredients can be helpful in managing the condition. Androgenetic alopecia and telogen effluvium comprise two of the main types of hair loss, and differ in their pathophysiology. The objective of the study was to evaluate, in male and female individuals with androgenetic alopecia and telogen effluvium, the safety and efficacy of a new hair loss lotion containing a combination of cosmetic ingredients: oleanolic acid, apigenin, biotinyl tripeptide-1, 2-4diamino pyrimidine-3-oxide, adenosine, Ginkgo biloba, and biotin. Methods: 56 patients with androgenetic alopecia (AGA) or telogen effluvium (TE) completed the study. For 6 months, the product was applied once-daily before bed and left on overnight. Efficacy and safety assessments took place at baseline, 3 months and 6 months. Efficacy was assessed in three ways: phototrichogram to count the total number of hairs and number and of hairs in telogen and anagen, visual clinical assessment by a dermatologist using a 7 point scale that evaluated hair volume/thickness, scalp coverage and overall hair appearance, and patient opinion questionnaire on the effects and additional qualities of the product. Results: In the whole study sample, the total number of hairs and number of anagen hairs increased significantly (p<0.05). In the subgroup with TE, there was a significant increase in total hairs, and in the AGA subgroup there was a significant increase in total hairs and anagen hairs. On visual clinical assessment, 35.7% of participants were evaluated as having thicker, more voluminous hair, 37.5% had improved general hair appearance and 39.3% had improved scalp coverage. On patient questionnaire, participants reported a reduction in hair loss (79%), increased confidence regarding their hair (86%) and that their hair problem was less visible (79%). The product was rated positively by 100% of participants for texture, smell, and hair condition. There were no adverse events. Conclusion: This lotion enriched with a mixture of oleanolic acid, apigenin, biotinyl tripeptide-1, 2-4 diamino pyrimidine-3-oxide, adenosine, Ginkgo biloba, and biotin is safe and effective as a topical hair-loss treatment, as proven by the statistically significant increase in total hair fibers and anagen hairs, the increased thickness and scalp coverage on dermatological assessment, and patient self-assessment.

Vacuum Therapy in Association with Plant Active Compounds, Prebiotics and Probiotics for Treatment of Androgenetic Alopecia, Female Pattern Hair Loss and Telogen Effluvium

Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia

Preparation and Optimization of Garlic Oil/Apple Cider Vinegar Nanoemulsion Loaded with Minoxidil to Treat Alopecia

Treatment of Androgenetic Alopecia Using PRP to Target Dysregulated Mechanisms and Pathways

Fractional CO2 laser, platelet rich plasma and combination of both in treatment of female pattern hair loss

Randomized Clinical Trial to Evaluate the Effect of Probiotic Intake on Androgenic Alopecia

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies

Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study

Biomolecules of Fermented Tropical Fruits and Fermenting Microbes as Regulators of Human Hair Loss, Hair Quality, and Scalp Microbiota

Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia

Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial

Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment

Management of androgenic alopecia: a systematic review of the literature

Predictive Metagenomic Profiling, Urine Metabolomics, and Human Marker Gene Expression as an Integrated Approach to Study Alopecia Areata

Clinical study on the efficacy and tolerability of an oral supplement based on arginine, l-cystine, zinc and B6 vitamin (Cystiphane®) in patients with telogen effluvium

Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field

Efficacy and Safety of a New Topical Hair Loss-Lotion Containing Oleanolic Acid, Apigenin, Biotinyl Tripeptide-1, Diaminopyrimidine Oxide, Adenosine, Biotin and Ginkgo biloba in Patients with Androgenetic Alopecia and Telogen effluvium: A Six-month Open-Label Prospective Clinical Study

An Updated Etiology of Hair Loss and the New Cosmeceutical Paradigm in Therapy: Clearing ‘the Big Eight Strikes’

Evaluating treatments for male androgenetic alopecia: clinical profile and comparative efficacy of platelet rich plasma and minoxidil with finasteride

Systematic review of mesotherapy: a novel avenue for the treatment of hair loss